Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 07, 2014 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Positive European Scientific Advice Meeting Regarding RHB-102 and Plans to Submit a European Marketing Application

The Company concluded a positive scientific advice meeting with the UK MHRA regarding RHB-102 and plans to submit, during the second half of the year, a European marketing application for the...
March 07, 2014 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the 26th Annual ROTH Conference

TEL-AVIV, Israel, March 7, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on...
March 07, 2014 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Provides Update on RHB-102 Development and Intellectual Property

RHB-102 is a proprietary once-daily oral antiemetic RedHill has secured from Temple University direct rights to the original RHB-102 patents and has terminated its agreement with SCOLR...
March 03, 2014 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film

TEL-AVIV, Israel, March 3, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and...
February 27, 2014 08:01 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma and Salix Pharmaceuticals Announce Worldwide Exclusive License Agreement for RedHill's RHB-106 Encapsulated Bowel Preparation

TEL-AVIV, Israel, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Salix Pharmaceuticals Ltd. (Nasdaq:SLXP) and RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) today announced that they have entered into an...
February 25, 2014 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Reports 2013 Fourth Quarter and Year-End Financial Results

2013 Key Highlights Include: Strong cash position of over $34 million, as of February 2014, following two private placements in early 2014 and the exercise of warrants, including by directors...
February 04, 2014 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma and IntelGenx Receive Complete Response Letter From FDA for RHB-103 Oral Film for Acute Migraines

FDA's letter accepted the bioequivalence study and safety information submitted and requires no additional clinical studies; RedHill and IntelGenx plan to address remaining issues, primarily...
January 22, 2014 06:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Closes Previously Announced $11.7 Million Private Placement

TEL-AVIV, Israel, Jan. 22, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on...
January 14, 2014 06:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Definitive Agreement for $11.7 Million Private Placement

TEL-AVIV, Israel, Jan. 14, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on...
January 06, 2014 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Provides Update on PK Program in Support of Ongoing RHB-104 Phase III Crohn's Study

Preliminary positive safety results received from a Phase I study with RHB-104 in 84 healthy adult subjects Additional PK studies with RHB-104 are planned, including long-term population PK...